Abstract
Co-morbid physical illness has been suggested to play an important role among the factors contributing to treatment resistance in patients with major depressive disorder. In the current study we compared the rate of physical co-morbidity, defined by ICD-10, among a large multicenter sample of 702 patients with major depressive disorder. A total of 356 of the participants were defined as treatment resistant depression (TRD) patients-having failed two or more adequate antidepressant trials. No significant difference was found between TRD and non-TRD participants in the prevalence of any ICD-10 category. This finding suggests that although physical conditions such as diabetes, thyroid dysfunction, hypertension, ischemic heart disease, and peptic diseases are often accompanied by co-morbid MDD, they do not necessarily have an impact on the course of MDD or the likelihood to respond to treatment. Marginally higher rates of co-morbid breast cancer, migraine and glaucoma were found among TRD participants. Possible explanations for these findings and their possible relation to TRD are discussed.
Original language | English |
---|---|
Pages (from-to) | 895-901 |
Number of pages | 7 |
Journal | European Neuropsychopharmacology |
Volume | 23 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2013 |
Externally published | Yes |
Bibliographical note
Funding Information:This study was supported by an unrestricted grant from Lundbeck for the Group for the Study of the Resistant Depression (GSRD). Lundbeck had no further role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.
Funding Information:
Spindelegger C. has received a travel grant from Lundbeck, and speaker's fees from Bristol-Myers Squibb.
Funding
This study was supported by an unrestricted grant from Lundbeck for the Group for the Study of the Resistant Depression (GSRD). Lundbeck had no further role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. Spindelegger C. has received a travel grant from Lundbeck, and speaker's fees from Bristol-Myers Squibb.
Funders | Funder number |
---|---|
H. Lundbeck A/S | |
H. Lundbeck A/S |
Keywords
- Depression
- Physical co-morbidity
- Treatment resistance
- Treatment response